140 related articles for article (PubMed ID: 34185343)
1. Outcomes of 756 patients with differentiated thyroid cancer and excellent response to treatment: An evidence-based paradigm for long-term surveillance strategies.
Seejore K; Mulla O; Gerrard GE; Gill VM; Al-Qaissi A; Moor JW; Murray RD
Clin Endocrinol (Oxf); 2022 Mar; 96(3):395-401. PubMed ID: 34185343
[TBL] [Abstract][Full Text] [Related]
2. Can We Discharge Dynamically Risk-Stratified Low-Risk (Excellent Response to Treatment) Thyroid Cancer Patients After 5 Years of Follow-Up?
Seejore K; Gerrard GE; Gill VM; Murray RD
Clin Oncol (R Coll Radiol); 2019 Apr; 31(4):219-224. PubMed ID: 30744934
[TBL] [Abstract][Full Text] [Related]
3. Postoperative Surveillance in Older Adults With T1N0M0 Low-risk Papillary Thyroid Cancer.
Pradhan MC; Kazaure HS; Wang F; Zambeli-Ljepovic A; Perkins JM; Stang MT; Scheri RP
J Surg Res; 2021 Aug; 264():37-44. PubMed ID: 33765509
[TBL] [Abstract][Full Text] [Related]
4. Age, thyroglobulin levels and ATA risk stratification predict 10-year survival rate of differentiated thyroid cancer patients.
Kelly A; Barres B; Kwiatkowski F; Batisse-Lignier M; Aubert B; Valla C; Somda F; Cachin F; Tauveron I; Maqdasy S
PLoS One; 2019; 14(8):e0221298. PubMed ID: 31425569
[TBL] [Abstract][Full Text] [Related]
5. Dynamic risk stratification system in post-lobectomy low-risk and intermediate-risk papillary thyroid carcinoma patients.
Cho JW; Lee YM; Lee YH; Hong SJ; Yoon JH
Clin Endocrinol (Oxf); 2018 Jul; 89(1):100-109. PubMed ID: 29672893
[TBL] [Abstract][Full Text] [Related]
6. Response to Therapy Assessment in Intermediate-Risk Thyroid Cancer Patients: Is Thyroglobulin Stimulation Required?
Moreno I; Hirsch D; Duskin-Bitan H; Dicker-Cohen T; Shimon I; Robenshtok E
Thyroid; 2020 Jun; 30(6):863-870. PubMed ID: 31928205
[No Abstract] [Full Text] [Related]
7. Evaluating the 2015 American Thyroid Association Risk Stratification System in High-Risk Papillary and Follicular Thyroid Cancer Patients.
van Velsen EFS; Stegenga MT; van Kemenade FJ; Kam BLR; van Ginhoven TM; Visser WE; Peeters RP
Thyroid; 2019 Aug; 29(8):1073-1079. PubMed ID: 31140385
[No Abstract] [Full Text] [Related]
8. Dynamic Risk Stratification in the Follow-Up of Children and Adolescents with Differentiated Thyroid Cancer.
Zanella AB; Scheffel RS; Nava CF; Golbert L; Laurini de Souza Meyer E; Punales M; Gonçalves I; Dora JM; Maia AL
Thyroid; 2018 Oct; 28(10):1285-1292. PubMed ID: 30129889
[TBL] [Abstract][Full Text] [Related]
9. IS IT WORTH SUPPRESSING TSH IN LOW- AND INTERMEDIATE-RISK PAPILLARY THYROID CANCER PATIENTS BEFORE THE FIRST DISEASE ASSESSMENT?
Lamartina L; Montesano T; Falcone R; Biffoni M; Grani G; Maranghi M; Ciotti L; Giacomelli L; Ramundo V; Lomonaco C; Di Gioia CR; Piernatale L; Ronga G; Durante C
Endocr Pract; 2019 Feb; 25(2):165-169. PubMed ID: 30383494
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of patients with differentiated thyroid cancer risk-stratified according to the American thyroid association and Latin American thyroid society risk of recurrence classification systems.
Pitoia F; Bueno F; Urciuoli C; Abelleira E; Cross G; Tuttle RM
Thyroid; 2013 Nov; 23(11):1401-7. PubMed ID: 23517313
[TBL] [Abstract][Full Text] [Related]
11. Modified dynamic risk stratification system further predicts individual outcome in patients with intermediate-risk papillary thyroid cancer.
Cuéllar DI; De Los Reyes A; Llamas-Olier A
Ann Endocrinol (Paris); 2023 Apr; 84(2):242-248. PubMed ID: 35483449
[TBL] [Abstract][Full Text] [Related]
12. Is TSH suppression still necessary in intermediate- and high-risk papillary thyroid cancer patients with pre-ablation stimulated thyroglobulin <1 ng/mL before the first disease assessment?
Tian T; Huang R; Liu B
Endocrine; 2019 Jul; 65(1):149-154. PubMed ID: 30924085
[TBL] [Abstract][Full Text] [Related]
13. Patient Age Is an Independent Risk Factor of Relapse of Differentiated Thyroid Carcinoma and Improves the Performance of the American Thyroid Association Stratification System.
Trimboli P; Piccardo A; Signore A; Valabrega S; Barnabei A; Santolamazza G; Di Paolo A; Stati V; Chiefari A; Vottari S; Simmaco M; Ferrarazzo G; Ceriani L; Appetecchia M; Giovanella L
Thyroid; 2020 May; 30(5):713-719. PubMed ID: 31973653
[No Abstract] [Full Text] [Related]
14. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system.
Tuttle RM; Tala H; Shah J; Leboeuf R; Ghossein R; Gonen M; Brokhin M; Omry G; Fagin JA; Shaha A
Thyroid; 2010 Dec; 20(12):1341-9. PubMed ID: 21034228
[TBL] [Abstract][Full Text] [Related]
15. Intermediate-Risk Papillary Thyroid Cancer: Risk Factors for Early Recurrence in Patients with Excellent Response to Initial Therapy.
Llamas-Olier AE; Cuéllar DI; Buitrago G
Thyroid; 2018 Oct; 28(10):1311-1317. PubMed ID: 30105948
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcome of differentiated thyroid cancer in children and young adults: risk stratification by ATA criteria and assessment of pre-ablation stimulated thyroglobulin as predictors of disease persistence.
Karapanou O; Tzanela M; Rondogianni P; Dacou-Voutetakis C; Chiotis D; Vlassopoulou B; Vassiliadi D; Kanaka-Gantenbein C; Tsagarakis S
Endocrine; 2020 Dec; 70(3):566-574. PubMed ID: 32533509
[TBL] [Abstract][Full Text] [Related]
17. Practical Performance of the 2015 American Thyroid Association Guidelines for Predicting Tumor Recurrence in Patients with Papillary Thyroid Cancer in South Korea.
Lee SG; Lee WK; Lee HS; Moon J; Lee CR; Kang SW; Jeong JJ; Nam KH; Chung WY; Jo YS; Lee J
Thyroid; 2017 Feb; 27(2):174-181. PubMed ID: 27750028
[TBL] [Abstract][Full Text] [Related]
18. Predictive Value of Serum Thyroglobulin for Structural Recurrence Following Lobectomy for Papillary Thyroid Carcinoma.
Xu S; Huang H; Zhang X; Huang Y; Guan B; Qian J; Wang X; Liu S; Xu Z; Liu J
Thyroid; 2021 Sep; 31(9):1391-1399. PubMed ID: 34340593
[No Abstract] [Full Text] [Related]
19. Papillary thyroid carcinoma patients assessed to be at low or intermediary risk after primary treatment are at greater risk of long term recurrence if they are thyroglobulin antibody positive or do not have distinctly low thyroglobulin at initial assessment.
Soyluk O; Boztepe H; Aral F; Alagol F; Özbey NC
Thyroid; 2011 Dec; 21(12):1301-8. PubMed ID: 22136265
[TBL] [Abstract][Full Text] [Related]
20. Frequent screening with serial neck ultrasound is more likely to identify false-positive abnormalities than clinically significant disease in the surveillance of intermediate risk papillary thyroid cancer patients without suspicious findings on follow-up ultrasound evaluation.
Peiling Yang S; Bach AM; Tuttle RM; Fish SA
J Clin Endocrinol Metab; 2015 Apr; 100(4):1561-7. PubMed ID: 25632970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
